NEW YORK – After years developing technology to do multiplex testing for infectious diseases, Enigma Diagnostics shuttered about two years ago without much fanfare. But thanks to a former investor in the company, Enigma's technology may live on.
NEW YORK – After years developing technology to do multiplex testing for infectious diseases, Enigma Diagnostics shuttered about two years ago without much fanfare. But thanks to a former investor in the company, Enigma's technology may live on.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.